Showing results (141-150 of 177) with videos related to

Sort By:
Pageof 18
Neurology. Clinical Practice|October 14, 2024
Characterizing Prodrome (Premonitory Phase) in Migraine: Results From the PRODROME Trial Screening PeriodTodd J Schwedt, Richard B Lipton, Peter J Goadsby, et al.
Physical Review Letters|February 9, 2005
Direct observation of itinerant magnetism in the 5f-electron system UTeT Durakiewicz, C D Batista, J D Thompson, et al.
American Journal of Human Genetics|January 1, 1991
Identification of a highly polymorphic microsatellite VNTR within the argininosuccinate synthetase locus: exclusion of the dystonia gene on 9q32-34 as the cause of dopa-responsive dystonia in a large kindredD J Kwiatkowski, T G Nygaard, D E Schuback, et al.
Cephalalgia : an International Journal of Headache|September 15, 2021
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trialTodd J Schwedt, Richard B Lipton, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Scientific Reports|September 14, 2013
Probing the interplay between quantum charge fluctuations and magnetic ordering in LuFe2O4J Lee, S A Trugman, C D Batista, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|November 1, 1994
Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystoniaS B Bressman, A L Hunt, G A Heiman, et al.
JAMA Network Open|June 8, 2022
Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical TrialRichard B Lipton, Patricia Pozo-Rosich, Andrew M Blumenfeld, et al.
Neurology|June 26, 2024
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS TrialPeter J Goadsby, Deborah I Friedman, Dagny Holle-Lee, et al.
Pageof 18